Concurrent administration of granulocyte colony-stimulating factor or granulocyte-monocyte colony-stimulating factor enhances the biological activity of rituximab in a severe combined immunodeficiency mouse lymphoma model.

Concurrent administration of granulocyte colony-stimulating factor or granulocyte-monocyte colony-stimulating factor enhances the biological activity of rituximab in a severe combined immunodeficiency mouse lymphoma model.

Item
http://www.wikidata.org/entity/Q40355709
The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implicationsImmune Cells in Cancer Therapy and Drug DeliveryA humanized HLA-DR antibody (hu1D10, apolizumab) in combination with granulocyte colony-stimulating factor (filgrastim) for the treatment of non-Hodgkin's lymphoma: a pilot studyRituximab resistance.C-type lectin-like molecule-1 (CLL1)-targeted TRAIL augments the tumoricidal activity of granulocytes and potentiates therapeutic antibody-dependent cell-mediated cytotoxicityMacrophages as mediators of tumor immunosurveillanceCD70 as a therapeutic target in human malignancies.GM-CSF plus rituximab immunotherapy: translation of biologic mechanisms into therapy for indolent B-cell lymphomas.Polymorphonuclear neutrophils and cancer: intense and sustained neutrophilia as a treatment against solid tumors.Enhancement of the anti-tumor activity of therapeutic monoclonal antibodies by CXCR4 antagonists.Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo.Involvement of neutrophils and natural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor models.Differential gene expression in non-malignant tumour microenvironment is associated with outcome in follicular lymphoma patients treated with rituximab and CHOP.Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model.
P2860

Concurrent administration of granulocyte colony-stimulating factor or granulocyte-monocyte colony-stimulating factor enhances the biological activity of rituximab in a severe combined immunodeficiency mouse lymphoma model.

Item
http://www.wikidata.org/entity/Q40355709
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Concurrent administration of g ...... ficiency mouse lymphoma model.
@en
type
label
Concurrent administration of g ...... ficiency mouse lymphoma model.
@en
prefLabel
Concurrent administration of g ...... ficiency mouse lymphoma model.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P577
P698
P356
P1433
P1476
Concurrent administration of g ...... ficiency mouse lymphoma model.
@en
P2093
P2860
P304
P31
P356
P433
P478
P577
P698